Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin + voriconazole vs voriconazole for primary therapy of invasive aspergillosis
2007-002445-20Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in invasive aspergillosis (IA) and aspergillosis comparing Anidulafungin + voriconazole with Voriconazole monotherapy (2 arms). Primary endpoint: All-cause mortality at 6 weeks. Started Oct 2007; status: completed.
02
Drugs
anidulafunginvoriconazole
03
Conditions
invasive aspergillosis (IA)aspergillosis
Beyond the preview
Go deeper on 2007-002445-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002445-20.